Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 401–500 of 913
Pael receptor is involved in dopamine metabolism in the nigrostriatal system
Imai, Y., Inoue, H., Kataoka, A., Wang, H., Masuda, M., Ikeda, T., Tsukita, K., Soda, M., Kodama, T., Fuwa, T., et al. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.08.005 · Cited by 49
Kinsella, R. L., Kimmey, J. M., Smirnov, A., Woodson, R., Gaggioli, M. R., Chavez, S. M., Kreamalmeyer, D., & Stallings, C. L. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002159 · Cited by 50
“Parkin -/- (Jax # 006582) [91], Pink1 -/- (Jax # 017946) [56], and WT control mice were a gift from Dr. Jonathan Brestoff at Washington University School of Medicine.”
BackgroundMethodOlanow, C. W., & Kordower, J. H. (2009) · Annals of Neurology · doi:10.1002/ana.21832 · Cited by 53
“Initial transgenic models that knocked out or carried a mutant form of Parkin were disappointing and did not replicate PD pathology or behavior.(18,19) However, Lu et al.”
BackgroundWenqiang, C., Lonskaya, I., Hebron, M. L., Ibrahim, Z., Olszewski, R. T., Neale, J. H., & Moussa, C. E.-H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu211 · Cited by 44
“Homozygous parkin (22), hemizygous transgenic mice harboring wild type human TDP-43 (TDP-43 mice) (23) and hemizygous mice harboring the A315T mutation (A315T mice) (24) were treated with intraperitoneal (i.”
BackgroundMethodSynergistic Effects of Ginkgolide B and Protocatechuic Acid on the Treatment of Parkinson’s Disease
Wu, T., Fang, X., Xu, J., Jiang, Y., Cao, F., & Zhao, L. (2020) · Molecules · doi:10.3390/molecules25173976 · Cited by 44
“A large number of autopsy reports of Parkinson’s disease patients have shown that oxidative stress can significantly reduce the levels of antioxidant protection systems (GSH, SOD and CAT), reduce the activity of mitochondrial complex enzyme I, and eventually lead to the degeneration of dopaminergic neurons in the midb…”
BackgroundGenetic Mouse Models of Neurodegenerative Diseases
Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 58
“Deletion of exon 3 in one KO model causes a mild decrease in nigrostriatal dopaminergic transmission and reduced synaptic excitability of striatal neurons but without dopaminergic neuronal loss up to 2 years of age.(137) A second KO model generated through deletion of exon 7 exhibits a normal number of nigrostriatal d…”
BackgroundMartella, G., Platania, P., Vita, D., Sciamanna, G., Cuomo, D., Tassone, A., Tscherter, A., Kitada, T., Bonsi, P., Shen, J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.11.001 · Cited by 46
“In agreement with previous reports (Goldberg et al., 2003; Kitada et al., 2007), medium spiny neurons (MSNs) recorded from both PINK1, Parkinmice aswell as from their respectiveWT littermates exhibited no significant changes in their intrinsic membrane properties.”
MethodSelf-citationFunctional Genomics meets neurodegenerative disorders
Hoerndli, F. J., David, D. C., & Götz, J. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.07.002 · Cited by 46
Loss-of-Function Rodent Models for Parkin and PINK1
Oliveras-Salv´, M., Van Rompuy, A.-S., Heeman, B., Van den Haute, C., & Baekelandt, V. (2011) · Journal of Parkinson's Disease · doi:10.3233/jpd-2011-11041 · Cited by 43
“established breeding colonies on a 129Sv background and on a 50/50% mixed 129SV/C57BL6 background [39] whereas two other groups generated mice lacking exon 3 on a mixed C57BL6/129SV background of unspecified proportions [40, 41].”
BackgroundInfluentialBertolin, G., Jacoupy, M., Traver, S., Ferrando-Miguel, R., Saint-Georges, T., Grenier, K., Ardila-Osorio, H., Mp, M., Takahashi, H., Lees, A. J., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2014.224 · Cited by 48
Altered Corticostriatal Neurotransmission and Modulation in Dopamine Transporter Knock-Down Mice
Wu, N., Cepeda, C., Zhuang, X., & Levine, M. S. (2007) · Journal of Neurophysiology · doi:10.1152/jn.00971.2006 · Cited by 43
“Interestingly, in these mouse models DA transmission is also significantly altered (Goldberg et al. 2003; Johnson et al. 2006).”
BackgroundSelf-citationDeletion of theparkinandPACRGgene promoter in early-onset parkinsonism
Lesage, S., Periquet, M., Lohmann, E., Lacomblez, L., Teive, H. A. G., Janin, S., Cousin, P.-Y., Dürr, A., Brice, A., & for the French Parkinson Disease Genetics Study Group (2006) · Human Mutation · doi:10.1002/humu.20436 · Cited by 43
“Unlike parkin knockout mice that have no or subtle behavioral phenotypes [Goldberg et al., 2003; Itier et al., 2003; Perez and Palmiter, 2005], qkv mice have a quaking phenotype, abnormal locomotion and tremor, and tonic/clonic seizures in adults [Lockhart et al., 2004; Lorenzetti et al., 2004a].”
Role of Mitochondrial Nucleic Acid Sensing Pathways in Health and Patho-Physiology
Chowdhury, A., Witte, S., & Aich, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.796066 · Cited by 43
What have we learned from Drosophila models of Parkinson’s disease?
Guo, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84001-4 · Cited by 51
Parkinson's disease, proteins, and prions: Milestones
Olanow, C. W., & McNaught, K. S. P. (2011) · Movement Disorders · doi:10.1002/mds.23767 · Cited by 55
Liu, B., Traini, R., Killinger, B. A., Schneider, B. L., & Moszczyńska, A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.01.001 · Cited by 43
Wang, H. B., Whittaker, D. S., Truong, D. A., Mulji, A., Ghiani, C. A., Loh, D. H., & Colwell, C. S. (2017) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2016.12.002 · Cited by 44
“The challenging beam test used is a modified version of the beam traversal test previously described (Carter et al., 1999; Goldberg et al., 2003), and used to characterize the motor deficits of BACHD and Q175 mutant mice in previous studies (Loh et al.”
MethodGezer, A. O., Kochmanski, J. J., VanOeveren, S., Cole-Strauss, A., Kemp, C. J., Patterson, J. R., Miller, K. M., Kuhn, N. C., Herman, D. E., McIntire, A., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104947 · Cited by 48
Self-citationRegulation of DNA repair by parkin
Kao, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.048 · Cited by 48
“Wild-type and parkin / mouse ES cells were provided by Matthew Goldberg and Jie Shen [18].”
MethodWei, F., Gao, G., Zhao, H., Xia, Y., Guo, X., Li, N., Li, Y., Yang, Y., Chen, L., Wang, Q., et al. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.030 · Cited by 45
“In the PD models of Parkin and α-synuclein gene mutation, manifestations of PD emerged and the tyrosine hydroxylase (TH)positive nerve terminals decreased in the striatum when the apoptosis of dopaminergic neurons was not observed (Goldberg et al., 2003; Lee et al., 2006).”
Cortese, G. P., Zhu, M. J., Williams, D. J., Heath, S. L., & Waites, C. L. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1473-16.2016 · Cited by 40
“, 2014), and multiple groups have reported that Parkin loss of function alters glutamatergic synaptic transmission and plasticity (Goldberg et al., 2003; Itier et al., 2003; Helton et al., 2008; Kitada et al., 2009; Hanson et al., 2010; Rial et al., 2014).”
BackgroundInfluentialModeling Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem Cells
Li, H., Jiang, H., Zhang, B., & Feng, J. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181353 · Cited by 51
“In contrast to the situation in PD patients with parkin mutations, parkin knockout mice [84, 85] or rats [86] do not exhibit any significant degeneration of nigral DA neurons or PD-like locomotor symptoms.”
ResultBasal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum
Creed, R. B., Menalled, L., Casey, B., Dave, K. D., Janssens, H. B., Veinbergs, I., van der Hart, M., Rassoulpour, A., & Goldberg, M. S. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.033 · Cited by 41
“Although the expression of these genes is not restricted to the nigrostriatal pathway, many studies have suggested they could be important for regulating neurotransmitter release, reuptake or turnover (Goldberg et al., 2003;Goldberg et al., 2005;Kitada et al., 2007;Melrose et al., 2010).”
Self-citationGenetic Mapping of Canine Multiple System Degeneration and Ectodermal Dysplasia Loci
O’Brien, D. P. (2005) · Journal of Heredity · doi:10.1093/jhered/esi086 · Cited by 46
“In humans, Purkinje cell loss and atrophy of the olivary nucleus occurs in some of the hereditary spinocerebellar ataxias ( Evidente et al. 2000 ) and in multiple system atrophy (MSA) (Wenning et al. 1997; Quinn 1989).”
BackgroundParkin affects mitochondrial function and apoptosis in neuronal and myogenic cells
Kuroda, Y., Mitsui, T., Kunishige, M., & Matsumoto, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.201 · Cited by 54
Mitophagy in Neurons: Mechanisms Regulating Mitochondrial Turnover and Neuronal Homeostasis
Basak, B., & Holzbaur, E. L. F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169161 · Cited by 46
Parkinson’s disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons
Zhu, M. J., Cortese, G. P., & Waites, C. L. (2018) · BMC Biology · doi:10.1186/s12915-018-0567-7 · Cited by 46
PINK1-Parkin signaling in Parkinson’s disease: Lessons from Drosophila
Imai, Y. (2020) · Neuroscience Research · doi:10.1016/j.neures.2020.01.016 · Cited by 48
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice
Aniszewska, A., Bergström, J. J. E., Ingelsson, M., & Ekmark‐Lewén, S. (2022) · Brain and Behavior · doi:10.1002/brb3.2628 · Cited by 44
“About 80% of PD patients develop dementia and 20–55% of nondemented PD patients display mild cognitive impairment (reviewed in [Goldman & Litvan, 2011]).”
BackgroundFunctional Genomics meets neurodegenerative disorders
David, D. C., Hoerndli, F. J., & Götz, J. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.07.001 · Cited by 41
Transgenic animal models of neurodegeneration based on human genetic studies
Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0476-6 · Cited by 39
“Several laboratories have generated parkin knockout mice by targeting different exons of the parkin gene (Bonifati et al. 2003; Goldberg et al. 2003; Palacino et al. 2004; Von Coelln et al. 2004; Perez et al. 2005; Sato et al. 2006).”
Seita, Y., Tsukiyama, T., Iwatani, C., Tsuchiya, H., Matsushita, J., Azami, T., Okahara, J., Nakamura, S., Hayashi, Y., Hitoshi, S., et al. (2016) · Scientific Reports · doi:10.1038/srep24868 · Cited by 40
Midnolin is a novel regulator of parkin expression and is associated with Parkinson’s Disease
Obara, Y., Imai, T., Sato, H., Takeda, Y., Kato, T., & Ishii, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-05456-0 · Cited by 40
Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics
Chandra, G., Shenoi, R. A., Anand, R., Rajamma, U., & Mohanakumar, K. P. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.12.004 · Cited by 39
Comprehensive Perspectives on Experimental Models for Parkinson’s Disease
Ke, M., Chong, C., Zhu, Q., Zhang, K., Cai, C.-Z., Lu, J., Qin, D., & Su, H. (2021) · Aging and Disease · doi:10.14336/ad.2020.0331 · Cited by 44
Mechanistic contributions of FBXO7 to Parkinson disease
Joseph, S., Schulz, J. B., & Stegmüller, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14253 · Cited by 42
Fox, S. N., McMeekin, L. J., Savage, C. H., Joyce, K. L., Boas, S. M., Simmons, M. S., Farmer, C. B., Ryan, J., Pereboeva, L., Becker, K., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00369-w · Cited by 41
Han, R., Wang, Q., Xiong, X., Chen, X., Tu, Z., Li, B., Zhang, F., Chen, C., Pan, M., Xu, T., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179633 · Cited by 45
Therapeutic strategies in Parkinson's disease: what we have learned from animal models
Valadas, J. S., Vos, M. H., & Verstreken, P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12577 · Cited by 45
Parkin reverses TDP ‐43‐induced cell death and failure of amino acid homeostasis
Hebron, M. L., Chen, W., Miessau, M., Lonskaya, I., & Moussa, C. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12630 · Cited by 41
Impaired Neurotransmitter Release in Alzheimer’s and Parkinson’s Diseases
Shen, J. (2010) · Neurodegenerative Diseases · doi:10.1159/000285511 · Cited by 38
“Furthermore, inactivation of each or all three of these recessive PD genes does not cause dopaminergic neurodegeneration [31, 33–35] .”
Self-citationKubo, S., Hattori, N., & Mizuno, Y. (2006) · Movement Disorders · doi:10.1002/mds.20841 · Cited by 45
Neuronal Preconditioning Requires the Mitophagic Activity of C-terminus of HSC70-Interacting Protein
Lizama, B. N., Palubinsky, A. M., Raveendran, V. A., Moore, A. M., Federspiel, J. D., Codreanu, S. G., Liebler, D. C., & McLaughlin, B. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0699-18.2018 · Cited by 37
“These data stand in stark contrast to Parkin-deficient models, which are neurochemically, behaviorally, and structurally indistinguishable from littermates (Goldberg et al., 2003; Palacino et al., 2004; Perez and Palmiter, 2005; Lizama et al., 2018).”
BackgroundResultProteomics in neurodegeneration – disease driven approaches
Schulenborg, T., Schmidt, O., van Hall, A., Meyer, H. E., Hamacher, M., & Marcus, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0512-8 · Cited by 39
“Parkin-knock out mice and flies do not show nigrostriatal neuron degeneration, but mitochondrial dysfunctions typically observed in sporadic PD (Goldberg et al., 2003).”
Backgroundl-DOPA Impairs Proteasome Activity in Parkinsonism through D1Dopamine Receptor
Berthet, A., Bézard, E., Porras, G., Fasano, S., Barroso‐Chinea, P., Dehay, B., Martínez, A., Thiolat, M.-L., Nosten‐Bertrand, M., Giros, B., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1541-11.2012 · Cited by 43
“129S4-Park2 tm1Shn/J (The Jackson Laboratory)] bearing a germline disruption of exon 3 were generated by in vivo homologous recombination as previously described (Goldberg et al., 2003).”
Methodvan der Vlag, M., Havekes, R., & Heckman, P. R. A. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14689 · Cited by 38
“Mouse models showed no clear phenotype but did show behavioural changes (Goldberg et al., 2003) and a general increased cellular sensitivity to apoptosis (Casarejos et al., 2006).”
BackgroundCox, R. T., Poulton, J., & Williams, S. A. (2021) · Reproduction and Fertility · doi:10.1530/raf-21-0060 · Cited by 39
Animal models in neurodegenerative diseases
Hirsch, É. C. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_11 · Cited by 44
“Parkin KO mouse no no no yes Itier et al. (2003), Goldberg et al. (2003) , Palacino et al. (2004) and Von Coelln et al. (2004)”
BackgroundGubellini, P., Picconi, B., Filippo, M. D., & Calabresi, P. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.001 · Cited by 45
Regulation of clathrin‐mediated endocytosis by p53
Endo, Y., Sugiyama, A., Li, S., Ohmori, K., Ohata, H., Yoshida, Y., Shibuya, M., Takei, K., Enari, M., & Taya, Y. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01172.x · Cited by 37
“Indeed, various mice deficient in endocytic regulators such as Hip1, c-Cbl and Parkin responsible for EGFR internalization are viable without obvious abnormalities (Murphy et al. 1998; Naramura et al. 1998; Rao et al. 2001; Goldberg et al. 2003).”
BackgroundManganese Inhalation as a Parkinson Disease Model
Ordóñez-Librado, J. L., Anaya-Martínez, V., Gutiérrez-Valdez, A. L., Colín-Barenque, L., Montiel-Flores, E., & Ávila-Costa, M. R. (2010) · Parkinson s Disease · doi:10.4061/2011/612989 · Cited by 43
Baptista, M. A. S., Dave, K. D., Sheth, N. P., Silva, S. N. D., Carlson, K. M., Aziz, Y. N., Fiske, B. K., Sherer, T., & Frasier, M. A. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.011940 · Cited by 44
“, 2003) but do exhibit elevated extracellular dopamine levels (Goldberg et al., 2003), enhanced dopamine metabolism (Itier et al.”
InfluentialCasarejos, M. J., Solano, R. M., Menéndez, J., Rodríguez‐Navarro, J. A., Correa, C., de Yébenes, J. G., & Mena, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03249.x · Cited by 40
Hallmarks and Molecular Tools for the Study of Mitophagy in Parkinson’s Disease
Goiran, T., Eldeeb, M. A., Zorca, C. E., & Fon, E. A. (2022) · Cells · doi:10.3390/cells11132097 · Cited by 43
RBR Ubiquitin Ligases: Diversification and Streamlining in Animal Lineages
Marín, I. (2009) · Journal of Molecular Evolution · doi:10.1007/s00239-009-9252-3 · Cited by 41
“Loss of function mutations in the parkin gene lead to just subtle anomalies in mice and human, in this last case leading, a considerable time after birth, to Parkinson disease (Kitada et al. 1998; Goldberg et al. 2003; Itier et al. 2003; Palacino et al. 2004; Perez and Palmiter 2005).”
BackgroundGene-Targeting Technologies for the Study of Neurological Disorders
Beglopoulos, V., & Shen, J. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:6:1:013 · Cited by 41
“…these mouse models display several pathological and behavioral phenotypes, such as increased extracellular dopamine concentration in the striatum (Goldberg et al., 2003), inhibition of amphetamine-induced dopamine release (Itier et al., 2003), impairments in mitochondrial function (Palacino et…”
BackgroundSelf-citationFernagut, P. O., Meissner, W. G., Biran, M., Fantin, M., Bassil, F., Franconi, J. M., & Tison, F. (2014) · Synapse · doi:10.1002/syn.21719 · Cited by 35
“Increased sensitivity of beam walking tasks over the rotarod has also been previously reported in parkin knockout mice (Goldberg et al., 2003) and mice expressing A30P alpha-synuclein (Plaas et al.”
BackgroundIncreasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene
Cognata, V. L., Iemmolo, R., D’Agata, V., Scuderi, S., Drago, F., Zappia, M., & Cavallaro, S. (2014) · Current Genomics · doi:10.2174/1389202915666140426003342 · Cited by 38
Loss of pdr-1/parkin influences Mn homeostasis through altered ferroportin expression in C. elegans
Chakraborty, S., Chen, P., Bornhorst, J., Schwerdtle, T., Schumacher, F., Kleuser, B., Bowman, A. B., & Aschner, M. (2015) · Metallomics · doi:10.1039/c5mt00052a · Cited by 36
Mooli, R. G. R., Mukhi, D., Watt, M., Edmunds, L. R., Xie, B., Capooci, J., Reslink, M. C., Eze, C., Mills, A. M., Stolz, D. B., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154225 · Cited by 33
“Generation of global Parkin knockout (Park2−/−) mice has been described before [21].”
BackgroundParkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 37
Parkinson’s Disease: From Genetics and Epigenetics to Treatment, a miRNA-Based Strategy
Paccosi, E., & Proietti‐De‐Santis, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119547 · Cited by 64
“Briefly, mutations in PRKN disrupt its E3 activity, resulting in the accumulation of α-Syn and the selective death of neurons in the substantia nigra [53].”
BackgroundAgeta‐Ishihara, N., Yamakado, H., Morita, T., Hattori, S., Takao, K., Miyakawa, T., Takahashi, R., & Kinoshita, M. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-35 · Cited by 38
“The second step is supported by the facts that SEPT5 overexpression interferes with syntaxin-mediated exocytosis from cultured cells [8,9], that parkin-null mice exhibit reduced synaptic excitability of the striatal medium spiny neurons and a mild motor coordination deficit [10], and that the dominant-negative parkin…”
BackgroundResultGonzález, S. R., Mena, M. A., Lastres‐Becker, I., Serrano, A., de Yébenes, J. G., Ramos, J. A., & Fernández‐Ruíz, J. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.010 · Cited by 38
Ubiquitin domain proteins in disease
Madsen, L., Schulze, A., Seeger, M., & Hartmann‐Petersen, R. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s1 · Cited by 40
“To date, two Park2 knockout mouse models have been reported [66,67], both of which are viable and fertile.”
BackgroundSanchez, G. M., Varaschin, R. K., Büeler, H., Marcogliese, P. C., Park, D. S., & Trudeau, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094826 · Cited by 48
“Finally, a number of authors reported mild alterations in locomotor function in Parkin KO, DJ-1 KO, Pink1 KO and LRRK2 transgenic mice [9,31,33,34,38].”
BackgroundThe role of E3 ubiquitin ligases in synapse function in the healthy and diseased brain
Kawabe, H., & Stegmüller, J. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103602 · Cited by 35
Li, J., Dang, X., Franco, A., & Dorn, G. W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.868465 · Cited by 43
Vecchia, E. D., Mortimer, N., Palladino, V. S., Kittel‐Schneider, S., Lesch, K., Reif, A., Schenck, A., & Norton, W. (2018) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000211 · Cited by 41
“Park2 /− mice did not show impairment of general activity, coordination, and gait performance (Goldberg et al., 2003; Perez and Palmiter, 2005; Rial et al., 2014) or display any olfactory changes (Kurtenbach et al.”
BackgroundThe neuronal ubiquitin-proteasome system: Murine models and their neurological phenotype
van Tijn, P., Hol, E. M., van Leeuwen, F. W., & Fischer, D. F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.001 · Cited by 39
“synphilin-1 and also levels of a-synuclein were unaltered (Goldberg et al., 2003), whereas proteomic analysis of ventral midbrain tissue of these mice revealed changes in proteins involved in regulation of mitochondrial function and oxidative stress (Palacino et al.”
InfluentialPathologic and therapeutic implications for the cell biology of parkin
Charan, R. A., & LaVoie, M. J. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.008 · Cited by 34
“Despite the intriguing phenotype of the parkin-null fly, parkin knockout mice do not display the severe mitochondrial defects expected in brain and do not display a conspicuous parkinsonian phenotype (Goldberg et al., 2003; Perez and Palmiter, 2005).”
BackgroundAnimal models of mitochondrial DNA transactions in disease and ageing
Oliveira, M. T., Garesse, R., & Kaguni, L. S. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.01.019 · Cited by 42
Sensory neuropathy and nociception in rodent models of Parkinson's disease
Valek, L., Auburger, G. W. J., & Tegeder, I. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039396 · Cited by 37
Zhang, S., Zhao, J., Quan, Z., Li, H., & Qing, H. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.853911 · Cited by 43
Structure-based design and characterization of Parkin-activating mutations
Stevens, M., Croteau, N., Eldeeb, M. A., Antico, O., Zeng, Z. W., Toth, R. L., Durcan, T. M., Springer, W., Fon, E. A., Muqit, M. M. K., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201419 · Cited by 35
“Although PRKN KO mice do not display neuron loss (Goldberg et al, 2003), they exhibit de fi cits in striatal neuron excitability and perturbation in mitochondrial proteins and respiration (Palacino et al, 2004; Periquet et al, 2005).”
BackgroundBasal activity of PINK1 and PRKN in cell models and rodent brain
Watzlawik, J. O., Fiesel, F. C., Fiorino, G., Bustillos, B. A., Baninameh, Z., Markham, B. N., Hou, X., Hayes, C. S., Bredenberg, J. M., Kurchaba, N. W., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2286414 · Cited by 34
“Consistent with the design of the mutant strain, in which EGFP was inserted into exon 3 to effectively disrupt the Prkn gene [14], an antibody against the N terminus of PRKN (PRKN 5C3) detected a band corresponding to a truncated form of PRKN (aa 1–95) fused to EGFP.”
BackgroundSelf-citationMitochondrial Pathobiology in Parkinson's Disease and Amyotrophic Lateral Sclerosis
Martin, L. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100348 · Cited by 32
“dysfunction [78], although this finding has not been confirmed in another mouse line [79].”
Yang, H., Zhou, H., Li, B., Niu, G., & Chen, S. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9082-2 · Cited by 32
“This observation is consistent with previous research result by Goldberg et al. (2003), who discovered that, in the Parkin knockout mouse model, brain tissue morphology was grossly normal, and the number of dopaminergic neurons in the substantia nigra was not significantly reduced.”
ResultProgrammed cell death and new discoveries in the genetics of parkinsonism
Burke, R. E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05106.x · Cited by 38
Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism
Song, L., McMackin, M. Z., Nguyen, A., & Cortopassi, G. A. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.024 · Cited by 32
“…in themitochondrial quality control gene Parkin causes SN neurodegeneration and Parkinsonism in humans, but deletion of the Parkin gene does not cause neurodegeneration in mice, possibly because of their shorter lifespan, and lower absolute accumulation of mtDNA deletions (Goldberg et al., 2003).”
BackgroundClec16a is Critical for Autolysosome Function and Purkinje Cell Survival
Redmann, V., Lamb, C. A., Hwang, S., Orchard, R. C., Kim, S., Razi, M., Milam, A., Park, S., Yokoyama, C. C., Kambal, A., et al. (2016) · Scientific Reports · doi:10.1038/srep23326 · Cited by 31
Ubiquitination at the mitochondria in neuronal health and disease
Covill‐Cooke, C., Howden, J. H., Birsa, N., & Kittler, J. T. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.07.003 · Cited by 33
Hennis, M. R., Marvin, M. A., Taylor, C. M., & Goldberg, M. S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.009 · Cited by 32
Self-citationNovel models for Parkinson’s disease and their impact on future drug discovery
Trigo‐Damas, I., del Rey, N. L., & Blesa, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1428556 · Cited by 34
“Equally, models with a Parkin mutation showed no loss of SNc neurons [49,50] or any DA-related behavioral alterations, though some exhibited slightly impaired DA release [51].”
BackgroundEvidence of Neurobiological Changes in the Presymptomatic PINK1 Knockout Rat
Ferris, C. F., Morrison, T. R., Iriah, S. C., Malmberg, S., Kulkarni, P. P., Hartner, J. C., & Trivedi, M. S. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171273 · Cited by 34
“The Rota-Rod test isolates equilibrium and motor behavior using a cylindrical tube 4 cm in diameter rotating at an increasing frequency, and has previously been used to assess motor function in Parkinson’s models [14, 39, 40].”
More, S. V., Kumar, H., Kim, I., Koppula, S., Kim, B.-W., & Choi, D. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990059 · Cited by 32
α-synuclein and Parkinson’s disease: a proteomic view
Fasano, M., & Lopiano, L. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.239 · Cited by 35
Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss
Chemla, A., Arena, G., Sacripanti, G., Barmpa, K., Žagare, A., Garcia, P., Gorgogietas, V. A., Antony, P. M. A., Ohnmacht, J., Baron, A., et al. (2025) · Brain · doi:10.1093/brain/awaf051 · Cited by 37
ThePolgMutator Phenotype Does Not Cause Dopaminergic Neurodegeneration inDJ-1-Deficient Mice
Hauser, D. N., Primiani, C. T., Langston, R. G., Kumaran, R., & Cookson, M. (2015) · eNeuro · doi:10.1523/eneuro.0075-14.2015 · Cited by 28
“The general lack of dopamine neuronal degeneration has also been reported for parkin knockout (Goldberg et al., 2003; Itier et al., 2003), PINK-1 knockout (Kitada et al.”
BackgroundGawęda-Walerych, K., & Żekanowski, C. (2013) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2013-1931 · Cited by 32
“2006), or influence their levels in PD animal models (Goldberg et al. 2003).”
BackgroundHidden phenotypes of PINK1/Parkin knockout mice
Paul, S., & Pickrell, A. M. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.129871 · Cited by 37
Vos, M. H., & Klein, C. (2021) · Cells · doi:10.3390/cells10030579 · Cited by 34
Mitochondrial dysfunction in Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750811040032 · Cited by 30
Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced oxidative stress
Yu, F., & Zhou, J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.052 · Cited by 33
Trudler, D., Nash, Y., & Frenkel, D. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1399-z · Cited by 32
Cranial and related sensorimotor impairments in rodent models of Parkinson's disease
Fleming, S. M., Schallert, T., & Ciucci, M. R. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.034 · Cited by 38
Self-citationCremer, J. N., Amunts, K., Schleicher, A., Palomero‐Gallagher, N., Piel, M., Rösch, F., & Zilles, K. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.10.054 · Cited by 30
Franco, R., Rivas‐Santisteban, R., Navarro, G., Pinna, A., & Reyes‐Resina, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094643 · Cited by 33
“129S4-Prkntm1Shn/J X X Prkn KO mice Increased extracellular dopamine concentration in the striatum Deficits in behavioral tests [114]”
BackgroundSynphilin-1 transgenic mice exhibit mild motor impairments
Jin, H., Yamashita, H., Nakamura, T., Fukuba, H., Takahashi, T., Hiji, M., Kohriyama, T., & Matsumoto, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.073 · Cited by 32
Su, Y., Duan, J., Ying, Z., Hou, Y., Zhang, Y., Wang, R., & Deng, Y. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.045 · Cited by 30
“However, it has been reported that the concentrations of some Parkin substrates which are also key proteins for PD pathogenesis, such as CDCrel-1, synphilin-l and a-synuclein are not altered in parkin-null mice (Goldberg et al., 2003; Hattori and Mizuno, 2004).”
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.